Navigation Links
EntreMed Presents Initial Clinical Results for ENMD-2076
Date:2/9/2009

a A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 targets a defined set of kinases, including Flt-3 and FGFR3, which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commissio
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Cephasonics, a ... today announced the introduction of the cQuest ... network-based communications with all cQuest Ultrasound™ hardware ... technology, including this new capability, at Hospitalar ... Brazil from May 21-24.  Cephasonics ...
(Date:5/21/2013)... May 21, 2013 BioElectronics Corp. (PINKSHEETS: ... electronic devices, announced that CEO, Andrew ... the FDA,s Medical Advisory Committee, Orthopedic and Rehabilitation ... for over the counter sales. "It,s ... medical device classification schema," Whelan said.  "While the ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... 7 NeuroVasx, Inc. announced,today the completion of a private ... of Minneapolis, MN and the Stephens Group of Little,Rock, AR. ... also announced completion of long term follow up on 20,patients ... which was completed in May. The company intends to announce ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today announced ... DX(R) breast cancer test are scheduled to be ... Symposium, taking place,December 13-16, 2007. Oncotype DX is ... the likelihood of recurrence and the likelihood,of chemotherapy ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3
(Date:5/21/2013)... According to a May 13, 2013 New Zealand Herald ... Botox injections have become the most popular cosmetic procedure ... goo.gl/8iYbD). Although it is mostly associated with women, Botox ... facial wrinkles less visible by paralyzing facial muscles. The effects ... This means that people who are conscious about their looks ...
(Date:5/21/2013)... Angeles, CA (PRWEB) May 21, 2013 ... sports organization, and Bodybuilding.com, the largest online retailer of ... you a new reality-based sports show, Warrior Island. ... vote on; YouTube, Facebook & Twitter, with our unique ... Warrior Island maroons these elite fighters on an island ...
(Date:5/21/2013)... (May 21, 2013) Research into genetic features of ... of Colorado School of Medicine may lead to improved ... paper published online by JAMA . , The ... survival in some cases of pulmonary fibrosis, a chronic ... As a result of the study, researchers may want ...
(Date:5/21/2013)... The Las Vegas personal injury law firm Benson, Bertoldo, ... a senior at Coronado High School, is the winner of ... As the winner of the essay contest, Crawford received a ... 1, 2012 and ran through April 30th, 2013. Participating senior ... essay on “The Role of the civil tort system.” The ...
(Date:5/21/2013)... May 21, 2013 While North Carolina ... with comprehensive travel guides. Brunswick Plantation & Golf Resort ... that include access to 27 holes of "Top10" championship ... in North Carolina, knowing the Top 10 ... takes away the overwhelming task of selecting the course ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
... Recognize Efforts to Safeguard Sight, Promote Healthy Vision ... for Children and Expand Access to ... was recognized for providing important leadership on health care,policy issues ... the 34,000 member American Optometric Association (AOA).,Optometrists in West Virginia ...
... Will Follow 60,000 Women for 5 Years, ... aged 55,years and older have enrolled in a ... of osteoporosis across the globe. Launch of the,Global ... announced,today at ECCEO 8 (Eighth European Congress on ...
... at Tri-City Medical Center (TCMC) achieved union recognition,Wednesday ... Service,confirmed that caregivers strongly supported unionization and had ... TCMC caregivers become members of SEIU United Healthcare ... workers who have achieved industry a,voice on the ...
... month of tough breathing may help asthma sufferers breathe easier ... of Houston professor. , In a move that ... Oath first do no harm Richard Bond, associate ... medical taboo to treat asthma. Although counterintuitive, Bonds studies ...
... under control , , WEDNESDAY, April 9 (HealthDay News) -- In ... swept across eight Midwestern states, but a new study claims ... outbreak was limited, because the number of people in the ... high, explained study co-author Amy A. Parker, from the ...
... Mr. Muneo Takashi has been,named to head ... Organization,(JETRO Chicago). As the new Chief Executive Director, ... completing his assignment in Chicago., As Chief ... in its activities designed to facilitate business development,between ...
Cached Medicine News:Health News:Sen. Robert Byrd Receives AOA Health Care Leadership Award 2Health News:Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide 2Health News:Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide 3Health News:North County Caregivers Join United Healthcare Workers 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 3Health News:First do no harm? UH prof taking opposite approach to treat asthma 4Health News:Mumps Outbreak in Midwest Could Have Been Worse 2Health News:Mumps Outbreak in Midwest Could Have Been Worse 3Health News:Muneo Takashi Named Chief Executive Director of Japan's Midwest Trade Office 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: